Unlock instant, AI-driven research and patent intelligence for your innovation.

Cytotoxic T lymphocyte

a cytotoxic, t lymphocyte technology, applied in the field of t lymphocytes, can solve the problems of insufficient preparation of cells in a necessary amount for immunization, troublesome induction of a ctl utilizing the antigen peptide, and high labor intensity, and achieve excellent effect, excellent effect, and excellent effect of specific recognition

Inactive Publication Date: 2006-04-06
MIE UNIVERSITY +1
View PDF1 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0017] A first embodiment of the present invention relates to RNA-introduced T lymphocytes into which an RNA encoding an antigen of interest is introduced, the RNA-introduced T lymphocytes having an activity of inducing T lymphocytes which recognize the antigen. Such RNA-introduced T lymphocytes include, for example, CD4-positive cells activated by phytohemagglutinin. Such RNA-introduced T lymphocytes have an excellent effect that, for example, cytotoxic T lymphocytes which recognize an antigen can be induced by a simple technique. Here, such cytotoxic T lymphocytes can act specifically on organisms causing an infectious disease or tumor cells in individuals, especially Asian races, particularly Japanese, can exhibit a therapeutic action on a tumor, and can specifically cause cytolysis of target cells or cells presenting a specific antigen, cytokine release reaction and the like, in the individuals.
[0025] A ninth embodiment of the present invention relates to a tetramer for detecting T cell receptors possessed by the cytotoxic T lymphocytes in the fifth embodiment, which comprises a human major histo-compatibility antigen (HLA)-A24-restricted antigen peptide represented by SEQ ID NO: 1 or 2 or the functional derivative thereof. Such tetramer exhibits an excellent effect that, for example, the tetramer can monitor the cytotoxic T lymphocytes in the individuals.

Problems solved by technology

The antigen peptide, even if the antigen is the same, varies depending on the type of HLA, and induction of a CTL utilizing the antigen peptide is thus troublesome.
To solve this problem, various devices have been made, but satisfactory results have not been obtained yet at present.
In these antigen-presenting cells, however, there are some disadvantages that much labor is required to prepare the cells in a necessary amount to induce immunization.
Owing to use of the virus, however, there is the disadvantage of lacked generality.
With respect to the method of introducing the gene, introduction of the gene using a virus vector or a plasmid DNA has the disadvantage of generating a new variant in some cases by insertion of the gene into a chromosome.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cytotoxic T lymphocyte
  • Cytotoxic T lymphocyte
  • Cytotoxic T lymphocyte

Examples

Experimental program
Comparison scheme
Effect test

example 1

Identification of HLA-A2402-Restricted CTL Epitope (Antigen Peptide) Using HLA-A2402 Transgenic Mice

(1) Materials and Method

HHDA2402±β2m− / − mice

[0127] A DNA construct (HHDA2402) containing an HLA-A2402 leader sequence, human β2 microglobulin, HLA-A2402 α1 and α2 domains, an H-2Db α3 transmembrane domain, and a cytoplasm domain was constructed. The resulting construct was cloned into an expression vector pcDNA 3.1 (manufactured by Invitrogen Corporation). The HHDA2402 construct (4 kb SalI-NotI fragment) was injected into fertilized eggs of C57BL / 6 mice, to give HHDA2402-expressing mice. Then, the HHDA2404-expressing mice were bred with β2m− / − mice (manufactured by The Jackson Laboratory). The resulting HHDA2402±β2m± were bred with β32m− / − mice to give HHDA 2402±β2m− / − mice (referred to hereinafter as “HHDA2402 mice”).

(2) Cell Strain

[0128] TAP transporter-deficient strain T2 (J. Immunol., 167, p.2529-2537 (2001)) was transfected with an HLA-A2402 cDNA to prepare T2A24 strain. ...

example 2

Preparation of HLA-2402 Antigen Peptide-Specific Human Cytotoxic T Lymphocytes (CTLs) Using CD4-Positive PHA Blast Cells into which mRNA was Introduced

(1) Preparation of mRNA

[0144] MAGE-A4 plasmid and SAGE plasmid were linearized. The resulting products and T7 polymerase (trade name: mMESSAGE mMACHINE T7 Kit, manufactured by Ambion, Inc.) were used, to conduct in vitro transfer according to a manufacturer's manual. Thereafter, the resulting product was polyadenylated with poly A polymerase (trade name: Poly(A) Tailing Kit, manufactured by Ambion, Inc.) according to a manufacture's manual. The resulting RNA was stored at −80° C. until use.

(2) Preparation of CD4-Positive Phytohemagglutinin (PHA) Blast Cells

[0145] By using positive selection using MACS CD4 microbeads (manufactured by Miltenyi Biotec), fresh CD4-positive cells were separated from PBMC. The resulting CD4-positive cells were seeded on a 24-well plate (manufactured by Coming Incorporated) at a cell density of from 1 ...

example 3

SAGE715-723-Specific CD8+ T Cells are Induced from A2402-Positive Healthy Normal Humans with High Probability

In Vitro Induction of Human CTLs Using CD8− PBMC Pulsed with a Peptide

[0166] The number 1×107 of CD8-negative PBMC were pulsed with 10 μM peptide by incubation at room temperature for 1 hour and at 37° C. in 5% CO2 for 1 hour, in 200 μl RPMI1640 medium containing 25 mM Hepes, 10 wt % inactivated human AB-positive serum, 2 mM L-glutamine, 100 U / milliliter penicillin, and 100 μg / milliliter streptomycin. The resulting cells were used as antigen-presenting cells. The number 5×105 of CD8+ T cells that were separated were then stimulated by incubation for from 10 to 12 days with 1×106 cells of the peptide-pulsed CD8− PBMC. On Days 1, 4 and 7, half amount of the medium was exchanged with fresh one, and human IL-2 (20 IU / milliliter) and IL-7 (50 ng / milliliter) were added thereto. Culturing for induction was conducted in 200 μl RPMI1640 medium (containing 25 mM Hepes, 10 wt % inact...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Cytotoxicityaaaaaaaaaa
Compatibilityaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a T lymphocyte having an activity to induce a T lymphocyte recognizing an antigen and a technique to use the T lymphocyte.

Description

BACKGROUND OF THE INVENTION [0001] 1. Field of the Invention [0002] The present invention relates to T lymphocytes having an activity of inducing T lymphocytes which recognize an antigen, a method of inducing specific antigen-specific T lymphocytes, use of induced T lymphocytes as a therapeutic agent for cancer or an infectious disease, HLA-A2402-restricted cytotoxic T lymphocytes (CTLs) specific for a tumor-associated antigen, an antigen peptide recognized by the CTL, use of the antigen peptide as a CTL inducer and a therapeutic agent for cancer, and a tetramer formed by tetramerizing MHC / antigen peptide complexes which is useful for detection of the CTL. [0003] 2. Discussion of Related Art [0004] Among cytotoxic T lymphocytes (CTLs), there is a CTL capable of recognizing, by a specific T cell receptor (abbreviated hereinafter as “TCR”), a complex wherein an antigen peptide and a major histo-compatibility antigen MHC molecule encoded by a major histo-compatibility gene complex (abb...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00A61K39/00C12N5/08A61K35/14A61K38/00A61P31/00A61P35/00A61P37/04C07K14/74C12N5/0783C12N5/10C12N5/16C12N15/09C12Q1/02C12Q1/04
CPCA61K39/00A61K39/0011A61K48/00A61K2039/5154A61K2039/5156C12N5/0636A61P31/00A61P35/00A61P37/04
Inventor SHIKU, HIROSHIHIASA, ATSUNORIOKUMURA, SATOSHINAOTA, HIROAKIMIYAHARA, YOSHIHIRO
Owner MIE UNIVERSITY